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CC BY-NC-ND license (http://creatiObjective: The aim of the present study was to investigate the association between non
sentinel lymph node metastasis (NSLNM) and clinicopathological factors, particularly in the
case of sentinel lymph node (SLN) metastasis in one or two, in clinically node negative patients
with breast cancer.
Methods: Between 10/2010 and 10/2014, 350 sentinel lymph node biopsy (SLNB) were per-
formed in patients with histologically proven primary breast cancer in our clinic. The data
collection includes the following characteristics: age, pathological tumor size, histological
type, histological grade, lymphovascular invasion (LVI), number of positive SLN, size of the
SLN metastasis (macrometastasis, micrometastasis, isolated tumor cells), multifocality (MF),
extracapsuler invasion (ECI) of the SLN, the estrogen receptor (ER) status, the progesterone
receptor (PR) status and the Her 2 receptor status, Ki 67 reseptor status. Data were collected
retrospectively and then analyzed.
Results: A successful SLN biopsy were performed in 345 (98.5%) cases. SLN metastases were
detected in 110 (31.8%) cases. These patients then underwent axillary dissection; among these
patients, 101 (91.8%) had only one to two positive SLNs. Of the 101 patients with positive SLN
biopsies, 32 (31.6%) had metastases in the NSLNs. Univariate and multivariate analysis showed
that lymphovascular invasion, extracapsular invasion (ECI), Her-2 receptor positive, and Ki-67
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and but should be further validated in our institutions, different institutions and different pa-
tient groups prospectively.
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licenses/by-nc-nd/4.0/).1. Introduction
The status of the axillary lymph node (LN) is one of the most
important prognostic markers for invasive breast cancer.
Sentinel LN biopsy (SLNB) is an accepted method for iden-
tification of pathologic axillary status in early cancer cases
with clinically negative axilla, which allows for correct and
reliable staging of the axillary nodal status with signifi-
cantly decreased shoulder arm morbidity.1e4 When positive
LN metastasis is detected by SLNB, the patient undergoes
complete axillary LN dissection (ALND). However, previous
reports suggest that additional LN metastasis is not found
on axillary dissection in approximately 40e60% of clinically
node-negative patients.5e7 Furthermore, in a recent pro-
spective randomized study, omitting ALND did not affect
local control or prognosis for SLN-positive patients. The
Z0011 trial found that omitting ALND did not result in poor
survival or local control in SLN-positive patients with low T
stage, no more than two SLNs, and no gross extracapsular
extension in the involved nodes. The trial also indicated
that ALND should be avoided if SLN metastases (SLNMs) are
detected in only one or two nodes.8 Several authors have
suggested using nomograms and scoring systems to predict
the risk of non-SLMs (NSLNMs) to omit ALND and increase
the quality of life in the optimal management of patients
with early breast cancer.9e17 Although numerous studies
have been performed in this regard, it is not yet clear in
which subgroup of patients with a positive SLN ALND can be
safely omitted.
The aim of this study was to investigate the association
between NSLNM and clinicopathologic factors, particularly
in the case of SLNM in one or two nodes of clinically node-
negative patients with breast cancer.
2. Methods
Between October 2010 and October 2014, 350 SLNBs were
performed in patients with histologically proven primary
breast cancer in our clinic. Histological diagnosis was
confirmed by core-needle biopsy preoperatively (n Z 330)
or by frozen section (nZ 20) during the surgical procedure.
SLNBs were performed using blue dye and radiocolloid in-
jections. All patients received a lymphoscintigraphy either
on the day prior to or on the day of surgery. The dose of the
injected radioisotope was 20e30 MBq (on the day before
surgery) or 10e12 MBq (on the day of surgery). Patients
were surgically treated by either total mastectomy or
breast-conserving surgery. ALND was performed for Level I
and II LNs if any macrometastases or micrometastases in
SLN were detected in the frozen section analysis. In theB, et al., Prediction of nonsentine
Journal of Surgery (2016), http:/case of false negativity, ALND was performed in a second
operation. However, if SLNB failed, ALND was considered
ineludible. ALND was avoided in patients with isolated
tumor cells in SLN.
In this work, we aimed to evaluate the clinicopathologic
features to predict NSLNM in breast cancer patients with
one to two positive SLNs.
The following data were collected from all patients: age
(<50 years or 50 years), pathological tumor size (2 cm,
2e5cm,or>5cm),histological type (invasiveductal, invasive
lobular, or mixed), histological grade (I, II, or III), lympho-
vascular invasion (LVI; yes or no), number of positive SLNs,
size of the SLNM (macrometastasis, micrometastasis, or iso-
lated tumor cells), multifocality (yes or no), extracapsular
invasion (ECI) of the SLN (yes or no), estrogen receptor (ER)
status (negative or positive), progesterone receptor (PR)
status (negative or positive), HER2 receptor status (negative
or positive), and Ki-67 receptor status (<14% or >14%). Data
were collected retrospectively and then analyzed.
Informed consent was obtained from all patients. Data
were collected retrospectively. Exclusion criteria were as
follows: ductal carcinoma in situ, palpable regional LNs,
neoadjuvant chemotherapy, known allergic reactions to
blue dye or isotope, previous surgery in the ipsilateral
breast, pregnancy, and distant metastasis at diagnosis.
Informed consent was obtained from all patients.
Multiple breast cancer included both multifocal and
multicentric breast cancers. Multifocal breast cancer is
defined as a case in which multiple invasive foci existed in
the same quadrant, and multicentric cancer was defined as
one in which the multiple invasive lesions were inter-
spersed in the pleural quadrants.
Breast cancer was considered multifocal if two or more
lesions were located in the same quadrant and the dis-
tance between each lesion was <5 cm. If nodules arise in
different quadrants of the breast and/or if the distance
between each lesion was >5 cm, the cancer was consid-
ered multicentric. Treatment decision making was made
in a multidisciplinary tumor board setting attended by
surgeons, medical oncologists, and radiation oncologists
specializing in breast cancer. Based on size, metastasis
was divided into macrometastases, micrometastases, or
isolated tumor cells, according to the American Joint
Committee on Cancer Staging Classification (AJCC) of
Breast Cancer.18 Macrometastasis was defined as a cancer
focus measuring over 2 mm in the greatest diameter
within SNs. Micrometastasis was defined as a cancer focus
measuring between 0.2 mm and 2 mm in the greatest
diameter within SLN, and isolated tumor cells were
defined as cancer foci smaller than 0.2 mm across their
greatest diameter within SLN.l lymph node metastasis in breast cancer patients with one or two
/dx.doi.org/10.1016/j.asjsur.2016.06.001
Table 1 Results of univariate analysis of clinicopathologic
factors associated with NSLNM.
Variables Non-SLN () Non-SLN (þ) p
Patients (n) 69 32
Age (y), median 50.9  1.4 52.4  2.1 0.553
>50 38 (55.1%) 17 (55.1%) 0.885
<50 31 (44.9%) 15 (46.9%)
Tumor size (cm) 2.9  2.1 3.2  3 0.564
<2 cm 22 (31.9) 12 (37.5%) 0.537
2e5 cm 40 (58%) 15 (46.9%)
>5 cm 7 (10.1%) 5 (15.6%)
Tumor type 0.797
Ductal 64 (92.75%) 31 (96.88%)
Lobular 2 (2.9%) 1 (3.12%)
Mixed 3 (4.35%) 0
Histological grade 0.537
I 15 (21.7%) 4 (12.5%)
II 33 (47.8%) 18 (56.3%)
III 21 (30.5%) 10 (31.2%)
Lymphovascular
invasion
<0.001*
Yes 10 (14.5%) 17 (56.25%)
No 59 (85.5%) 15 (43.75%)
Multifocality 0.549
Yes 9 (13%) 6 (18.8%)
No 60 (87%) 26 (81.2%)
ER 0.991
Positive 56 (81.2%) 26 (81.3)
Negative 13 (18.8%) 6 (18.7%)
Progesterone
receptor
0.087
Positive 55 (79.7%) 20 (62.5%)
Negative 14 (20.3%) 12 (37.5%)
HER2 0.043*
Positive 12 (17.4%) 12 (37.5%)
Negative 57 (82.6%) 20 (62.5%)
Triple negative 0.929
Yes 4 2
No 65 30
Ki-67 0.011*
<14 41 (59.4%) 10 (31.2%)
>14 28 (40.6%) 22 (68.8%)
Removed SLN
number, median
2.0  0.1 2.2  0.1 0.145
Positive SLN, n
1 53 (76.8%) 20 (62.5%) 0.156
2 16 (23.2%) 12 (37.5%)
Size of metastasis in SLN 0.173
Macrometastasis 62 (90%) 31 (96.9%)
Micrometastasis 5 (7.2%) 0
Isolated tumor cells 2 (2.8%) 1 (3.1%)
Extracapsular invasion 0.003*
Yes 9 (13%) 13 (40.6%)
No 60 (87%) 19 (59.4%)
Surgery
Mastectomy 26 (39.13%) 16 (50%) 0.305
Breast-conserving
surgery
43 (60.87%) 16 (50%)
* Statistically significant (p < 0.05).
ER Z estrogen receptor; NSLNM Z nonsentinel lymph node
metastasis; SLN Z sentinel lymph node.
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+ MODELIn this study, the pathologic invasion size for multiple
breast cancer was based on the maximum diameter of each
invasive component, and total tumor size for multiple
breast cancer was defined as the maximum diameter of the
lesions.19 Diagnosis was made according to the AJCC and
World Health Organization criteria. Assessment of patho-
logical parameters followed standard guidelines.
ER, PR, and HER2 receptor statuses were established on
the resected primary tumor or on the core biopsy sample.
PR and ER statuses were assessed by Allred scores, with an
Allred score of 3 or more indicating ER or PR positivity.20,21
HER2 expression was examined by immunohistochemical
(IHC) analysis. A gene amplification assay using fluores-
cence in situ hybridization was used in cases where it was
difficult to decide the HER2 status by IHC. Ki-67 protein
expression was also examined by IHC, and the results are
expressed as the percentage of tumor cells stained by the
antibody, as described previously.22
Hematoxylineeosin staining was used to assess
lymphatic and vascular involvement, as well as histologic
grading, which was defined according to the Scarffe-
BloomeRichardson system.23 ECI was defined as positive if
extracapsular tumor growth was present in an SLN section.
Each SLN was bisected at two levels for hematoxylineeosin
staining with IHC staining for cytokeratin.
2.1. Statistical analysis
The associations between NSLNM and clinicopathologic
factors including age, invasive tumor size, nuclear grade,
lymphatic or venous involvement, ECI, ER and/or PR sta-
tus, HER2 status, and Ki-67 labeling index were examined.
All statistical analyses were performed using the IBM SPSS
Statistics 22.0 package program (IBM Corporation,
Armonk, NY, USA). Data were expressed as frequencies or
median (minimumemaximum). ShapiroeWilk test was
used and a histogram and the qeq plot were examined to
assess data normality. Statistical analyses were performed
using ManneWhitney U test and the Chi-square test.
Univariate and multiple binary logistic regression analyses
were performed for predicting NSLNM using independent
factors, such as HER2 status, Ki-67 labeling index, ECI, and
LVI. Each of the predictive variables (obtained by binary
logistic regression analysis) of sensitivity, specificity,
positive predictive values, negative predictive values, and
accuracy values was calculated to determine NSLNM. A
two-sided p value < 0.05 was considered to indicate sta-
tistical significance. Confidence interval (CIs) were set at
the 95% level.
3. Results
A successful SLN biopsy was performed in 345 (98.5%) cases.
SLNMs were detected in 110 (31.8%) patients. These pa-
tients then underwent ALND; among these patients, 101
(91.8%) had only one to two positive SLNs. Of the 101 pa-
tients with positive SLN biopsies, 32 (31.6%) had metastases
in the NSLNs. After ALND, five patients had SLNM on the
final pathology despite negative SLN during frozen section
analysis. Therefore, the false-negative rate was 4.3%
(5/115) in our study. The average number of harvested SLNBold values signifies statistically significant (p < 0.05).
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Table 2 Multiple binary logistic regression analysis for predicting clinicopathologic factors associated with nonsentinel lymph
node metastasis.
Variables Odds ratio (95% confidence interval) p
LVI 6.1 (2.1e17.69) 0.010
HER2 positive 3.2 (1.07e9.55) 0.037
Ki-67 index > 14 3.2 (1.53e9.27) 0.026
ECI 4 (1.24e12.7) 0.020
According to multiple logistic regression analysis, we obtained the following equation:
PðNSLNMZ1ÞZ 11þexpð 2:683þ1:185 Ki67 þ 1:165 HER2 þ 1:382 ECI þ 1:804 LVIÞ
ECI Z extracapsular invasion; LVI Z lymphovascular invasion.
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in patients with positive NSLNM (p Z 0.145).
The results of univariate analysis of clinicopathologic
factors associated with NSLNM are presented in Table 1.
Based on the results obtained, we investigated which fac-
tors were predictive of NSLNM in clinically node-negative
patients with breast cancer.
Histological type of the primary tumor was invasive
ductal carcinoma in 95 patients (94%), invasive lobular
carcinoma in three patients (3%), and mixed invasive breast
carcinoma in three patients (3%). There was no statistically
significant between the groups (pZ 0.797). The mean ages
(standard deviation) were 50.9  1.4 years in patients
with negative NSLN and 52.4  2.1 years in patients with
NSLNM (p Z 0.553).
The median invasive tumor size was larger in patients
with NSLNM compared with metastasis-negative patients
(3.2  3 vs. 2.9  2.1, respectively; p Z 0.564), but there
was no statistical significance.
Characteristics of study patients and results of the his-
topathological evaluation of the primary tumor are pre-
sented in Table 1. Demographics of study patients and
histopathological features of the primary tumor that were
likely to predict metastatic involvement of NSLN are pre-
sented in Table 2.
Univariate analysis showed that LVI, ECI, positive HER2
receptor, and Ki-67 index over 14% were associated with
NSLNM (p < 0.05; Table 1). There was no significant associ-
ation between NSLNM and invasive tumor size, nuclear
grade, ER and/or PR status, triple negative, multifocality,
positive SLN, and size ofmetastasis in SLN (p> 0.05, Table 1).Table 3 Overall prediction of nonsentinel lymph node
metastasis using variables obtained by multiple binary lo-
gistic regression analysis in patients with clinically node-
negative breast cancer.
Variables Truly positive
NSLNM
Truly negative
NSLNM
Total
Predicted positive
NSLNM
17 8 25
Predicted negative
NSLNM
15 61 76
Total 32 69 101
Variables obtained by multiple binary logistic regression anal-
ysis are presented in Table 2.
NSLNM Z nonsentinel lymph node metastasis.
Please cite this article in press as: O¨z B, et al., Prediction of nonsentine
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[odds ratio (OR)Z 6.1, 95% CIZ 2.1e17.69, pZ 0.01], HER2
receptor positivity (OR Z 3.2, 95% CI Z 1.07e9.55,
pZ 0.037), ECI (ORZ 4, 95% CIZ 1.24e12.7, pZ 0.02), and
Ki-67 index over 14% (OR Z 3.2, 95% CI Z 1.53e9.27,
pZ 0.026)were independent predictors for NSLNM (Table 2).
A total of 59 (58.4%) patients underwent breast-
conserving surgery and 42 (41.6%) received mastectomy.
There was no difference between the two groups regarding
the surgical method (positive NSLN vs. negative NSLN,
p Z 0.305; Table 1). Macrometastasis was observed in 93
(92%) patients, micrometastasis in five (5%) patients, and
isolated tumor cells in three (3%) patients.
The overall prediction of NSLNM based on variables ob-
tained in multiple binary logistic regression analysis (Table
2) is shown in Table 3. The overall sensitivity, specificity,
negative predictive value, positive predictive value, and
accuracy of the prediction model were 53.1%, 88.4%, 80.2%,
68.0%, and 77.2%, respectively (Table 4). Table 4 also shows
each independent predictor for NSLNM.
4. Discussion
The aim of our work was to evaluate the risk factors of
NSLNM in clinically node-negative breast cancer patients
with one to two SLNMs and examine the likelihood of NSLN
prediction. Our study results show that LVI, HER2 receptor
positivity, ECI, and Ki-67 index over 14% were independent
predictors for NSLNM.
Axillary nodal status is an important prognostic and
predictive factor for the staging and treatment of breast
cancer. SLNB is accepted as a standard procedure for axil-
lary lymph node staging in clinically axillary-negative
breast cancer patients?.24e26 However, 40e70% of patients
with positive SLN do not have further axillary metas-
tasis.27,28 Therefore, axillary dissection could be avoided in
these patients.9,12 Although ALND has been the standard
procedure if patients are positive for SLNM, a recent clin-
ical trial suggests that ALND is unnecessary if positive SLNM
is detected in one or two nodes. The ACOSOG Z0011 trial8
showed that SLNB alone without ALND results in
extremely low locoregional recurrence and excellent
overall survival comparable to that in patients undergoing
ALND if SLNM is present in two or fewer nodes. In addition,
the Dutch AMAROS trial29 compared ALND with radiotherapy
in T1eT2 patients with a positive SLNB. The trial authors
obtained similar results in terms of axillary control between
the two treatments. In that trial, patients treated withl lymph node metastasis in breast cancer patients with one or two
/dx.doi.org/10.1016/j.asjsur.2016.06.001
Table 5 Studies demonstrating independent predictors of NSLNM in clinically node-negative breast cancer, with different
rates of NSLNM, ERþ, T1, and MF.
Study NSLNM (%) Patients, n ERþ (%) T1 (%) Multifocality (%) Predictive factors
Toshikawa et al (2015)39 38.6 44 93.1 50 Unstudied factor tm size, LVI
Yıldız et al (2015)31 48.5 70 77.1 40 20 MF, tm size
Gurleyik et al (2011)34 22 59 71 66 Unstudied factor tm size, LVI
Su et al (2012)42 50.9 159 81.7 62.2 10.2 SLN number, negative
SLN number
Eldweny et al (2012)27 44.4 80 80 40 20 LVI
Dingemans et al (2016)13 58.8 158 78.4 31.6 18.9 tm size, ECI, negative
SLN number
Tan et al (2014)43 55.2 266 81.2 30.8 9 LVI, negative SLN number,
positive SLN number
Moosavi et al (2014)32 55 167 69.4 21.5 16.1 age, tm size,
LVI, ECI
Kuru et al (2014)33 48.5 237 88 37.1 14 tm size, LVI, ECI,
multifocality, negative
SLN number
Yeniay et al (2012)17 40.9 244 78.1 55 14.5 cerb-2, metastasis
size
Gipponi et al (2013)40 26.1 126 78.6 69.8 Unstudied factor tm size, LVI, grade,
mitoses number
Wang et al (2015)41 38.8 509 67.7 42 5 tm size, grade, LVI,
negative and positive
SLN number
Jinno et al (2008)35 35.1 131 73.2 Unstudied
factor
Unstudied factor LVI, positive SLN
number
Dozin et al (2014)36 35.5 397 74.6 64.7 Unstudied factor tm size,grade, HER2
res positive, positive
SLN number
Cabioglu et al (2012)30 37.9 116 Unstudied
factor
48.2 17.2 metastasis size,
ECI
Neven et al (2014)15 21.9 470 91.9 10.6 Unstudied factor SLNM size
Ozmen et al (2006)37 50.6 148 70.2 44 10.8 tm size, ECI,
SLNM size
Gur et al (2009)38 33.5 319 86.6 49.8 Unstudied factor tm size, SLNM size
Present study 31.6 101 81.1 33.6 14.8 LVI, ECI, Ki-67
level, HER2 positive
ECIZ extracapsular invasion; ERZ estrogen receptor; LVIZ lymphovascular invasion; MFZ multifocality; NSLNMZ nonsentinel lymph
node metastasis; SLN Z sentinel lymph node; tm Z tumor.
Table 4 Rates of specificity and sensitivity, PPV, NPV, and accuracy of values obtained by univariate binary logistic regression
analysis to predict NSLNM for each independent predictor.*
Variables Lymphovascular invasion HER2 positive Ki-67 index > 14 Extracapsular invasion Overalla
Sensitivity (%) 53.1 37.5 68.7 40.6 53.1
Specificity (%) 85.5 82.6 59.4 86.9 88.4
PPV (%) 62.9 50 44 40.6 68
NPV (%) 79.7 80.3 80.3 75.9 80.2
Accuracy (%) 75.2 68.3 62.3 72.2 77.2
NPV Z negative predictive value; PPV Z positive predictive value.
a The overall specificity, sensitivity, PPV, NPV, and accuracy values obtained by multiple binary logistic regression analysis to predict
NSLNM, which were calculated using Table 3.
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with radiotherapy. Based on this, many studies have iden-
tified factors associated with the histopathological vari-
ables of the primary tumor and the SLNM to developPlease cite this article in press as: O¨z B, et al., Prediction of nonsentine
positive sentinel lymph nodes, Asian Journal of Surgery (2016), http:/nomograms to predict the risk of NSLNM.13,15,17,27,30e41
These studies showed that different pathologic character-
istics of the primary tumor and the SN were associated with
an increased probability of additional positive NSLN.l lymph node metastasis in breast cancer patients with one or two
/dx.doi.org/10.1016/j.asjsur.2016.06.001
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NSLNM until now (Table 5).
Some histopathological variables of the primary tumor
and its metastasis have been identified to correlate with
the NSLN status. The most commonly analyzed risk factors
in other studies include primary tumor size, grade of pri-
mary tumor, the maximum size of positive SLN, LVI, ECI in
SLN, and ER, PR, and HER2 statuses (Table 5).
The association of tumor size with the probability of
NSLNM has been documented in numerous studies where the
T1 tumor rates ranged from 10% to 70% in the study
group.15,37e40 Ozmen et al37 also demonstrated that tumor
size over 2 cm was associated with a higher rate of SLNM and
NSLNM. Recently, Dingemans et al13 and Wang et al41 also
reported that the primary tumor size was a predictor of
NSLNM. Chen et al14 have recently developed a new nomo-
gram to predict the probability of a patient with one to two
metastatic SLN to have further axillary disease, which is
similar to our study, but they could not demonstrate an
association between tumor size and NSLN involvement in
multivariate analyses. Similarly, there was no correlation
between tumor size and NSLNM in our study. Although some
studies have shown that tumor size was not associated with
a higher rate of NSLNM17,27,42,43 in parallel to our study,
some studies have reported contrasting results.31,34,37,40
Some investigations have demonstrated that the pres-
ence of micrometastasis in SLN was associated with lower
rates of NSLNM, compared with macrometastasis.17,30,37 It
has also been reported that the size of the SLNM had no
significant relationship with NSLNM after multivariate
analysis.14,27,32,40 Similarly, in our study, the size of the
SLNM was not an independent predictor of NSLNM. The
Memorial Sloan Kettering Cancer Center (MSKCC) model,
which is the most widely used model to predict NSLNM, also
did not include the size of SLNM.9
To our knowledge, few studies have shown that age was
significantly associated with positive NSLNs in multivariate
analyses.32,44 However, several studies could not find an
association of age with NSLNM,15,34e43 which was the case
in this study as well.
Some investigations have revealed that LVI is a predictor
of NSLNM.27,33,35 In this study, we reported an association
between LVI and NSLN involvement. However, Yıldız et al31
and Dozin et al36 have recently demonstrated that LVI is not
a significant predictor of NSLNM in logistic regression
analysis. In our study, LVI at SLN was found to be a predictor
of NSLNM, although its sensitivity was low (53.1%) and
specificity was high (85.5%).
Recently, Shigematsu et al45 revealed that ECI at SLN is
an independent predictor of both NSLNM and poor prognosis
for early stage breast cancer patients with SLNM. Similarly,
we demonstrated that the presence of ECI at SLN was a
strong predictor of NSLNM, with 86.9% specificity. In addi-
tion, several studies have documented ECI to be a predictor
of NSLNM,13,32,33,37 although in some other studies this
relationship was not found.12,42
Some authors have revealed that multifocality of the
primary tumor is a predictor of NSLNM.31,33 In our study,
the relationship between multifocality of the primary
tumor and NSLNM was not significant in both
univariate and multivariate analyses, as seen in many
studies.12,37,39,41Please cite this article in press as: O¨z B, et al., Prediction of nonsentine
positive sentinel lymph nodes, Asian Journal of Surgery (2016), http:/Axillary LN involvement has been reported to be higher
in ER/PR-positive patients.46,47 However, in this study, we
did not find any relationship between ER/PR positivity and
NSLNM. Meretoja et al28 and Wang et al48 indicated that
there is a significant relation between HER2 expression and
NSLNM. Similarly, the results obtained in this study showed
that overexpression of HER2 significantly increased the
probability of NSLNM. However, several studies did not
demonstrate this relationship.7,10,12,48
In our study, Ki-67 index over 14 is a predictor of NSLNM
in both univariate and logistic regression analyses, but its
accuracy (68.7%) and specificity (59.4%) are lower than
other predictors. To our knowledge, only one study36
documented that Ki-67 level over 20% in SLN is signifi-
cantly related to NSLNM in univariate analyses, but not
significant in multivariate analysis. However, some studies
could not demonstrate this relationship.14,17,40 The authors
of the present paper opine that an association between Ki-
67 level and NSLNM has not been revealed in many
studies.13,27,30e32,42,43,45,49
Based on the obtained predictors of NSLNM in different
studies, several nomograms have been developed to pre-
dict the presence of tumor in NSLN in the axilla.9e12,33 The
most widely used nomogram is developed by MSKCC.9 This
nomogram includes primary tumor size, grade, number of
positive and negative SLNs, SLN detection method, ER sta-
tus, LVI, and tumor multifocality to predict NSLNM.
Although the predictive accuracy of these nomograms have
been validated by some studies,17,33,41,50 others have
not.42,49,51,52
In this study, the overall sensitivity, specificity, negative
predictive value, positive predictive value, and accuracy of
the prediction model were 53.1%, 88.4%, 80.2%, 68.0%, and
77.2%, respectively. Although our sensitivity value is low,
both specificity value and negative predictive value are
high. These data could better predict the condition of not
having an NSLNM in patients with positive SLN, compared
with other prediction values.
Recently, many mathematical models have been used to
evaluate the predictive factor of NSLNM in SLN-positive
patients. A literature review showed that many different
studies included various clinicopathologic factors or
different study designs (e.g., rate of T1 tumor, ER, multi-
focality, and NSLNM, as shown in Table 5). However, the
results of these studies cannot be applied to specific pa-
tient populations as they may have poor accuracy. There-
fore, each clinic should establish its own nomograms and
utilize the most appropriate nomogram or should determine
the likelihood of NSLNM to omit ALND.
The limitation of our study is that it is a retrospective
study using a single and small population. Despite these
limitations, our predictive model provides a good specificity
and negative predictive value for the prediction of NSLNM;
however, our model should be further validated in our in-
stitutions, different institutions, and different patient
groups prospectively.
In our study, the predictive factors of NSLNM were LVI,
ECI, Ki-67 level, and HER2 receptor positivity. Based on
these results, ALND may be omitted in consequence of
positive SLN in one or two nodes in clinically node negative
patients with breast cancer. Our results incidate more ac-
curate the patients with no evidence of NSLNM than that ofl lymph node metastasis in breast cancer patients with one or two
/dx.doi.org/10.1016/j.asjsur.2016.06.001
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+ MODELNSLNM due to high specificity rate and NPV obtained in the
predictive model. These factors should be validated in
prospective studies in order to develop a nomogram to
predict NSLNM before they can be used generally.References
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